Patient Education Materials
|
 |
How to avoid taking a HIT in the
hospital (ARG163)
Questions and answers about heparin and HIT if you or someone
you care about are considering surgery.
|
|
Download a digital
file now
Download PDF File
(file size: 453 k)
or
Click the box to order
by mail
|
|
 |
If You Have Been Diagnosed With
Heparin-Induced Thrombocytopenia (ARG169)
Common patient questions and answers on HIT.
|
|
Download the English
digital file now
Download PDF
File
(file size: 108 k)
Download the Spanish
digital file now
Download
PDF File
(file size: 95 k)
or
Click the box to order
English version by mail
Click the box to order
Spanish version by mail
|
|
Physician Clinical and Resource Materials
|
|
Argatroban Anticoagulation
During Percutaneous Coronary Intervention in Patients With
Heparin-Induced Thrombocytopenia (ARG058)
Lewis et al. Catheterization and Cardiovascular Interventions
57:177–184 (2002).
Heparin-induced thrombocytopenia (HIT) is an immune-mediated
syndrome associated with thrombosis. Alternative anticoagulation
to heparin is needed for HIT patients during percutaneous
coronary intervention (PCI). We evaluated argatroban, a direct
thrombin inhibitor, for anticoagulation in this setting. |
|
View
abstract now
or
Click the box to order
the full article by mail
|
|
|
Argatroban Anticoagulant Therapy
in Patients With Heparin-Induced Thrombocytopenia (ARG108)
Lewis et al. Circulation:103:14;1838-1843.
Heparin-induced thrombocytopenia (HIT) is an immune-mediated
syndrome caused by heparin with serious complications. We
report a prospective, historical-controlled study evaluating
the efficacy and safety of argatroban, a direct thrombin inhibitor,
as anticoagulant therapy in patients with HIT or HIT with
thrombosis syndrome (HITTS).
|
|
View
abstract now
or
Click the box to order
the full article by mail
|
|
|
Essential Q&A for Heparin-Induced
Thrombocytopenia (ARG117)
Dr. Jack Hirsh
Here, in a straightforward question-and-answer format, one
of the most renowned and experienced experts in the field
puts the diagnosis and treatment of HIT in current perspective.
|
|
Click the box to order
by mail
|
|
|
Argatroban Clinical Scenario Tool
(ARG124)
Key points in diagnosis and management of heparin-induced
thrombocytopenia (HIT).
|
|
Download a digital
file now
Download
PDF File
(file size: 240 k)
or
Click the box to order
by mail
|
|
|
Argatroban Anticoagulation in Patients
with Heparin-Induced Thrombocytopenia (ARG135)
Lewis, et al. Arch Intern Med. 2003;163:1849-1856.
HIT is an intensely prothrombotic syndrome managed by discontinuation
of heparin therapy and treatment with an alternative inhibitor
of thrombin. We describe our experience with argatroban, a
direct thrombin inhibitor, in patients with HIT or HIT with
thrombosis (HITTS).
|
|
View
abstract now
or
Click the box to order
the full article by mail
|
|
|
Heparin-Induced Thrombocytopenia
(HIT): A Challenge in Emergency Medicine (ARG165)
In an ongoing prospective study, antibodies that can cause
HIT were found in almost 10% of all patients presenting to
the Emergency Department with symptoms of thrombosis including
chest pain and a recent history of heparin exposure.
|
|
Download a digital
file now
Download PDF
File
(file size: 432 k)
or
Click the box to order
by mail
|
|
|
Delayed-Onset of Heparin-Induced
Thrombocytopenia and Thrombosis (ARG171)
Warkentin, TE and Kelton, JG. Ann Intern Med. 2001;135:502-506.
Author describes a syndrome termed delayed-onset heparin-induced
thrombocytopenia, in which thrombocytopenia and thrombotic
events begin 5 or more days after withdrawal of heparin.
|
|
Click the box to order
by mail
|
|
|
Delayed-Onset of Heparin-Induced
Thrombocytopenia (ARG172)
Rice L, et al. Ann Intern Med. 2002;136:210-215.
Author describes several clinical scenarios when the onset
or manifestations of heparin-induced thrombocytopenia were
delayed.
|
|
Click the box to order
by mail
|
|
|
Treatment of Heparin-Induced Thrombocytopenia
(ARG174)
Hirsh J, et al. Arch Intern Med. 2004;164:361-369.
This systematic review summarizes the risk for thrombosis
in HIT patients when heparin therapy is stopped; evidence
of the efficacy of thrombin inhibitors in patients with HIT
with and without thrombosis; evidence supporting the use of
thrombin inhibitors in patients with a history of HIT who
require a coronary intervention procedure; and the risk for
bleeding when antithrombotic agents are used.
|
|
View
abstract now
or
Click the box to order
the full article by mail
|
|
|
Argatroban Dosing in Patients with
Heparin-Induced Thrombocytopenia (ARG193)
Verme-Gibboney CN, Hursting MJ. Ann Pharmacother 2003;37:970-5.
Authors evaluated clinical experiences with argatroban dosing,
particularly incremental dosage adjustments, during a clinical
trial of argatroban anticoagulation in HIT.
|
|
View
abstract now
or
Click the box to order
the full article by mail
|
|
 |
HIT Myths and Misconceptions (ARG218)
Rice L. Arch Intern Med;164:1961-1964.
A discussion of the myths and misconceptions about HIT that
“will cause trouble for you and your patients.”
|
|
View
abstract now
or
Click the box to order
the full article by mail
|
|
|
Heparin-Induced Thrombocytopenia:
A Clinical Diagnosis Video (VHS/DVD) ARG237/ARG232
In this video, leading clinicians and researchers discuss heparin-induced
thrombocytopenia and the importance of making an accurate clinical
diagnosis as well as the treatment options available for patients
with or at risk for HIT.
|
|
Click the appropriate box to order by mail
VHS
DVD
|
|
|
Heparin-Induced Thrombocytopenia:
One Case at A Time (VHS/DVD) ARG228/ARG227
In this video, leading clinicians discuss heparin-induced thrombocytopenia
through a series of patient case presentations in a variety
of hospital settings and utilizing today's most relevant literature
and treatment recommendations.
View sample clips
|
|
Click the appropriate box to order by mail
VHS
DVD
|
|
|
| The Argatroban.com
Web site contains links to third-party Web sites on the Internet.
These links are provided as a service to individuals interested
in more information in HIT. These sites are not part of this GlaxoSmithKline
(GSK) Web site. The content and materials in these third-party Web
sites are not produced or endorsed by GSK and may refer to uses
of our products that are not recommended by GSK. |
